Erlotinib hydrochloride

Icotinib Hydrochloride (BPI-2009) is a potent and specific EGFR inhibitor with an IC 50 of 5 nM: also inhibits mutant EGFR L858R , EGFR L858R/T790M , EGFR T790M and EGFR L861Q .In VitroIncubation with Iconitib at 0.5 μM results in kinase activity

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC 50 s of116, 5, 1 nM for aurora A , aurora B , aurora C , respectively. Ilorasertib hydrochloride also is a potent VEGF , PDGF inhibitor.

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC 50 s of116, 5, 1 nM for aurora A , aurora B , aurora C , respectively. Ilorasertib hydrochloride also is a potent VEGF , PDGF inhibitor.

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC 50 s of116, 5, 1 nM for aurora A , aurora B , aurora C , respectively. Ilorasertib hydrochloride also is a potent VEGF , PDGF inhibitor.

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC 50 s of116, 5, 1 nM for aurora A , aurora B , aurora C , respectively. Ilorasertib hydrochloride also is a potent VEGF , PDGF inhibitor.

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC 50 s of116, 5, 1 nM for aurora A , aurora B , aurora C , respectively. Ilorasertib hydrochloride also is a potent VEGF , PDGF inhibitor.

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC 50 s of116, 5, 1 nM for aurora A , aurora B , aurora C , respectively. Ilorasertib hydrochloride also is a potent VEGF , PDGF inhibitor.

JBJ-09-063 hydrochloride is a mutant-selective allosteric EGFR inhibitor with IC50s of 0.147 nM, 0.

JBJ-09-063 hydrochloride is a mutant-selective allosteric EGFR inhibitor with IC50s of 0.147 nM, 0.

K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC 50 of 4.3 µM and a K i of 6.4 µM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis

K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC 50 of 4.3 µM and a K i of 6.4 µM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis

K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC 50 of 4.3 µM and a K i of 6.4 µM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis